Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus

Primary Objective:

To assess patient preference for Lantus SoloSTAR pen versus Lantus vial and syringe at the
end of Crossover Phase (Week 4) in patients with type 2 diabetes mellitus (T2DM)

Secondary Objectives:

To compare Lantus SoloSTAR pen versus Lantus vial and syringe with regard to the following
parameters:

Randomization/Crossover phase:

>Healthcare professional's (HCP) recommendation for Lantus SoloSTAR pen versus Lantus vial
and syringe

Re-randomization phase:

- change in Fasting plasma glucose (FPG) from week 4 to week 10

- Percentage of patients achieving FPG<110 mg/dL at week 10

- change in Lantus dose injected per day (U) from week 4 to wekk 10

Observational phase:

- percentage of patients achieving HbA1c goal (<7%) at week 40

- time to first observation of HbA1c<7% during the observational phase

- percentage of patients who discontinue investigational product (IP) during the
observational phase due to dissatisfaction with their current device

All phases:

- percentage of patients who discontinue IP during each phase of the study

- safety assessment such as occurrence of hypoglycemic events (HE) and adverse events
(AE)